Veneno Technology is a Tsukuba, Japan-based Novel DRP Drug Discovery Company. It raised $2M in Seed financing.
SBI Investment, Tsukuba Institute of Research, Ltd. and SBI led the round.
The funds will be used by the company to improve the organization and recruitment, to further develop its proprietary peptide-based drug discovery platform technology and to invest in research and development of its own drug discovery pipeline that uses DRP functional peptides for basic molecules. This will further encourage DRP drug discovery.
Veneno Technologies is a company that specializes in the research and development of peptide-DRPs for transporters, ion channels and other membrane proteins. Veneno Suite(tm), the company’s integrated DRP drug discovery platform, is a proprietary technology. It consists of a large gene collection that was created artificially by accelerating the evolution natural DRPs (Disulfide Rich Peptides). Using them as templates, a screening technology that allows the rapid and efficient search for target DRPs, and technology that allows the production of multiple DRPs in a very short time.